Announcement on Preliminary Earnings Estimate for 2024
Filed with SSE · · 3 pages · Chinese
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Later from Shanghai MicuRx Pharmaceutical
- MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
- Special Report on Deposit and Use of Raised Funds in 2024
- Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares Listing
- MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
- Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical